Back to search
FDAFDA · Food and drugs·Recall number Z-2431-2012

Sekisui Spectrolyse PAI-1, In-Vitro Diagnostic for Quantitative determination of Plasminogen Activator Inhibitor Type- 1 (PAI-1) activity in human plasma. Catalog Number: 101201 For the determination of Plasminogen Activator Inhibitor Type 1 (PAI-1) activity in human plasma. The test is for in Citro diagnostic use.

Published September 26, 2012 · Recall initiated: August 28, 2012

Summary

FDA records medical device Class II recall Z-2431-2012, published September 26, 2012 and initiated August 28, 2012. Recalling firm: Sekisui Diagnostics Llc; Status: Terminated; Reported quantity: 699 kits; Lot: Lot Numbers: 120425 and 120601. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

SPECTROLYSE PAI-1 activity assay producing lower than expected absorbance values with "0" standard. This will reduce the slope of the standard curve requiring the user to make more frequent sample dilutions.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Sekisui Diagnostics Llc
Distributor
Nationwide distribution: USA including states of: FL, IN, IL, and WA.
Lot
Lot Numbers: 120425 and 120601
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was Sekisui Spectrolyse PAI-1, In-Vitro Diagnostic for Quantitative determination of Plasminogen Activator Inhibitor Type- 1 (PAI-1) activity in human plasma. Catalog Number: 101201 For the determination of Plasminogen Activator Inhibitor Type 1 (PAI-1) activity in human plasma. The test is for in Citro diagnostic use. recalled?

Yes. FDA published recall Z-2431-2012 on September 26, 2012. Reported hazard: SPECTROLYSE PAI-1 activity assay producing lower than expected absorbance values with "0" standard. This will reduce the slope of the standard curve requiring the user to make more frequent sample dilutions.

What should I do if I have this product?

Voluntary: Firm initiated · Letter